The offering is a significant dilutive event for a pre-revenue company. Monitor the final prospectus for use of proceeds and any potential impact on CARVYKTI sales or pipeline funding. The stock may face near-term pressure from the dilution, but the cash raise could extend the runway for R&D.
Price Chart
Executive Summary
Legend Biotech announced a $226M underwritten public offering of 7.7M ADSs at $29.35 per ADS, with a 30-day option for an additional 1.155M ADSs. The offering is a dilutive capital raise, but the proceeds are not earmarked for a specific use, and the company is pre-revenue with CARVYKTI as its sole marketed product. The offering is expected to close on June 23, 2026.
Key Financial Metrics
Key Facts
- Legend Biotech is offering 7,700,000 ADSs at $29.35 per ADS, each representing two ordinary shares.
- Underwriters have a 30-day option to purchase up to an additional 1,155,000 ADSs at the same price.
- Gross proceeds expected to be approximately $226 million before expenses and underwriting discounts.
- Offering is expected to close on June 23, 2026, subject to customary conditions.
- Joint book-running managers: Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities.
- The company has over 3,000 employees and is the largest standalone cell therapy company.
- CARVYKTI is the sole marketed product, developed with Johnson & Johnson for multiple myeloma.
Financial Impact
~$226M gross proceeds from 7.7M ADSs at $29.35/ADS, representing ~7.7% dilution based on current shares outstanding (assuming 100M shares outstanding, ~7.7% new shares).
Risk Factors
- Dilution of ~7.7% of outstanding shares.
- No specific use of proceeds stated, raising uncertainty about capital allocation.
- Pre-revenue company with CARVYKTI as sole product; reliance on J&J for commercialization.
- Market conditions may affect closing or pricing of the offering.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3313891 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 6-K | $19.80 | awaiting T+20 | — | $21.43 (+8.23%) |
Oct 13, 2026 14d ago | 6-K | $17.88 | awaiting T+20 | — | $21.43 (+19.85%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $21.43 (+13.87%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $21.43 (+12.14%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $21.43 (+12.14%) |
Sep 15, 2026 6w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $21.43 (+21.28%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $21.43 (+15.65%) |
Aug 11, 2026 11w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $21.43 (−1.83%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $21.43 (−11.21%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $21.43 (+11.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers